Douglas Goumas, MD
Orthopaedic Surgery · Manchester, NHNPI 1285662759
Payments from drug & device makers
What this record shows
This record is dominated by education: $3,742 of the $6,041 with a category attached, or 61.9%. Arthrex accounts for 60.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $3,185 and has fallen 94.6% since, to $171 in 2025.
Across 60 payments — averaging $100.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$4K
- Kairos Surgical Inc$1K
- Pacira Pharmaceuticals Incorporated$220
- Stryker$167
- Bioventus LLC$160
- Endo USA, Inc.$84
- plus $383 from 10 others
What the payments were for
- Travel & lodging$88415%
- Food & beverage$1,41623%
- Education$3,74262%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 19 | $3,633 |
| Kairos Surgical Inc | 4 | $1,395 |
| Pacira Pharmaceuticals Incorporated | 8 | $220 |
| Stryker | 1 | $167 |
| Bioventus LLC | 6 | $160 |
| Endo USA, Inc. | 3 | $84 |
| Ferring Pharmaceuticals Inc. | 3 | $70 |
| Johnson & Johnson(2 entities) | 3 | $54 |
| Zimmer Biomet | 1 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Pacira Therapeutics, Inc. | 2 | $40 |
| Vertex | 2 | $35 |
| Fidia Pharma USA Inc. | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Si-bone, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,041 in reported general payments places this provider in the 70th percentile of 141 orthopaedic surgery providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 64 | $586 |
| Oxycodone Hcl | 75 | $384 |
| Celecoxib | 17 | $264 |
| Tramadol Hcl | 76 | $139 |
| Dexamethasone | 32 | $131 |
| Diclofenac Sodium | 14 | $80 |
| Gabapentin | 26 | $58 |
| Amoxicillin | 38 | $48 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Manchester
- Jason OlivieroManchester$5K
- Akhilesh SastryPortsmouth$966K
- Mayo NoerdlingerPortsmouth$529K
- John-Erik BellLebanon$528K
- Michael MorwoodPortsmouth$506K
- Ira ParsonsSomersworth$245K
- Alexander OremLebanon$215K
- David RichardsNashua$122K
- Philip WolinskyLebanon$110K
- Ida GitajnLebanon$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.